Cell metab:癌细胞为什么不睡觉?

2015-09-24 佚名 生物谷

本文亮点:   MYC和MYCN癌基因会扰乱体内分子的生物钟   MYC能够直接激活BMAL1-CLOCK的负调控因子   组成型激活负调控因子--REV-ERB会使生物钟暂停   生物钟暂停与代谢的昼夜波动紊乱相关     近日,来自美国宾夕法尼亚大学的研究人员在国际学术期刊cell metablism上发

本文亮点:

 
MYC和MYCN癌基因会扰乱体内分子的生物钟
 
MYC能够直接激活BMAL1-CLOCK的负调控因子
 
组成型激活负调控因子--REV-ERB会使生物钟暂停
 
生物钟暂停与代谢的昼夜波动紊乱相关
 

 
近日,来自美国宾夕法尼亚大学的研究人员在国际学术期刊cell metablism上发表了一项最新研究进展,他们发现癌基因MYC会通过改变节律调控因子的表达影响癌细胞增殖和代谢。
 
MYC基因编码的MYC是一种转录因子,它能够通过一些叫做E-box的位点(5`-CACGTG-3`)与基因组进行结合,而这种结合位点也是一种异二聚体节律调控转录因子--CLOCK-BMAL1与基因组结合所需要的特征性序列。因此,MYC的异常表达是否会通过扰乱E-box参与的节律网络干扰癌细胞的生物钟成为研究人员研究的重点。
 
在这项研究中,研究人员发现MYC以及N-MYC的表达失调都能够在体外直接诱导REV-ERBa,进一步抑制BMAL1的表达及正常波动以干扰细胞内的分子生物钟,并且这一现象可以通过敲低REV-ERBa的表达来进行挽救。
 
除此之外,REV-ERBa高表达和BMAL1低表达都可以对成神经细胞瘤病人较差的临床结果进行预测。研究人员将740名病人肿瘤样本的基因表达情况与病人的整体生存率进行了比较,发现两者确实具有相关性。除此之外,研究人员还在成神经细胞瘤细胞系中重新表达BMAL1,发现可以抑制癌细胞的增殖能力。他们还发现MYC对葡萄糖代谢的波动情况也有调节作用,还会干扰细胞对谷氨酰胺的消耗,这两种都是细胞所需的关键代谢分子。
 
这项研究让我们更清楚地认识到了癌细胞为什么以及如何有效劫持细胞的能量机制以保持快速增殖,同时也为癌症治疗方法的开发提供了新的信息。

原文出处:
 
Brian J. Altman17, Annie L.et al.MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells.Cell metab.2015

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1869217, encodeId=288d186921ed9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 01 02:01:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959472, encodeId=978d19594e2e7, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri May 13 14:01:00 CST 2016, time=2016-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895838, encodeId=da511895838a6, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Aug 05 23:01:00 CST 2016, time=2016-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887465, encodeId=5b97188e4652d, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Nov 30 18:01:00 CST 2015, time=2015-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252049, encodeId=6f811252049ac, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Sep 26 00:01:00 CST 2015, time=2015-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540668, encodeId=3db315406686d, content=<a href='/topic/show?id=be0ae30534b' target=_blank style='color:#2F92EE;'>#睡觉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73053, encryptionId=be0ae30534b, topicName=睡觉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb5913283122, createdName=tsing_hit, createdTime=Sat Sep 26 00:01:00 CST 2015, time=2015-09-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1869217, encodeId=288d186921ed9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 01 02:01:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959472, encodeId=978d19594e2e7, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri May 13 14:01:00 CST 2016, time=2016-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895838, encodeId=da511895838a6, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Aug 05 23:01:00 CST 2016, time=2016-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887465, encodeId=5b97188e4652d, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Nov 30 18:01:00 CST 2015, time=2015-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252049, encodeId=6f811252049ac, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Sep 26 00:01:00 CST 2015, time=2015-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540668, encodeId=3db315406686d, content=<a href='/topic/show?id=be0ae30534b' target=_blank style='color:#2F92EE;'>#睡觉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73053, encryptionId=be0ae30534b, topicName=睡觉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb5913283122, createdName=tsing_hit, createdTime=Sat Sep 26 00:01:00 CST 2015, time=2015-09-26, status=1, ipAttribution=)]
    2016-05-13 智智灵药
  3. [GetPortalCommentsPageByObjectIdResponse(id=1869217, encodeId=288d186921ed9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 01 02:01:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959472, encodeId=978d19594e2e7, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri May 13 14:01:00 CST 2016, time=2016-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895838, encodeId=da511895838a6, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Aug 05 23:01:00 CST 2016, time=2016-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887465, encodeId=5b97188e4652d, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Nov 30 18:01:00 CST 2015, time=2015-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252049, encodeId=6f811252049ac, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Sep 26 00:01:00 CST 2015, time=2015-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540668, encodeId=3db315406686d, content=<a href='/topic/show?id=be0ae30534b' target=_blank style='color:#2F92EE;'>#睡觉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73053, encryptionId=be0ae30534b, topicName=睡觉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb5913283122, createdName=tsing_hit, createdTime=Sat Sep 26 00:01:00 CST 2015, time=2015-09-26, status=1, ipAttribution=)]
    2016-08-05 一闲
  4. [GetPortalCommentsPageByObjectIdResponse(id=1869217, encodeId=288d186921ed9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 01 02:01:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959472, encodeId=978d19594e2e7, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri May 13 14:01:00 CST 2016, time=2016-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895838, encodeId=da511895838a6, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Aug 05 23:01:00 CST 2016, time=2016-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887465, encodeId=5b97188e4652d, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Nov 30 18:01:00 CST 2015, time=2015-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252049, encodeId=6f811252049ac, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Sep 26 00:01:00 CST 2015, time=2015-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540668, encodeId=3db315406686d, content=<a href='/topic/show?id=be0ae30534b' target=_blank style='color:#2F92EE;'>#睡觉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73053, encryptionId=be0ae30534b, topicName=睡觉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb5913283122, createdName=tsing_hit, createdTime=Sat Sep 26 00:01:00 CST 2015, time=2015-09-26, status=1, ipAttribution=)]
    2015-11-30 guojianrong
  5. [GetPortalCommentsPageByObjectIdResponse(id=1869217, encodeId=288d186921ed9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 01 02:01:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959472, encodeId=978d19594e2e7, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri May 13 14:01:00 CST 2016, time=2016-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895838, encodeId=da511895838a6, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Aug 05 23:01:00 CST 2016, time=2016-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887465, encodeId=5b97188e4652d, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Nov 30 18:01:00 CST 2015, time=2015-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252049, encodeId=6f811252049ac, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Sep 26 00:01:00 CST 2015, time=2015-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540668, encodeId=3db315406686d, content=<a href='/topic/show?id=be0ae30534b' target=_blank style='color:#2F92EE;'>#睡觉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73053, encryptionId=be0ae30534b, topicName=睡觉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb5913283122, createdName=tsing_hit, createdTime=Sat Sep 26 00:01:00 CST 2015, time=2015-09-26, status=1, ipAttribution=)]
    2015-09-26 yxch36
  6. [GetPortalCommentsPageByObjectIdResponse(id=1869217, encodeId=288d186921ed9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 01 02:01:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959472, encodeId=978d19594e2e7, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri May 13 14:01:00 CST 2016, time=2016-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895838, encodeId=da511895838a6, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Aug 05 23:01:00 CST 2016, time=2016-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887465, encodeId=5b97188e4652d, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Nov 30 18:01:00 CST 2015, time=2015-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252049, encodeId=6f811252049ac, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Sep 26 00:01:00 CST 2015, time=2015-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540668, encodeId=3db315406686d, content=<a href='/topic/show?id=be0ae30534b' target=_blank style='color:#2F92EE;'>#睡觉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73053, encryptionId=be0ae30534b, topicName=睡觉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb5913283122, createdName=tsing_hit, createdTime=Sat Sep 26 00:01:00 CST 2015, time=2015-09-26, status=1, ipAttribution=)]
    2015-09-26 tsing_hit

相关资讯

PNAS:揭示失灵的癌基因“刹车”

来自匹兹堡大学医学院的研究人员在一项新研究中证实,在头颈部癌中一种重要的癌基因活性增高是由于本应该抑制该基因的一些调控蛋白发生突变及功能异常所导致。这些研究结果在线发表在《美国科学院院刊》(PNAS)杂志上,为治疗头颈部癌以及其他的癌症提供了一个新的药物靶点。 论文的资深作者、匹兹堡大学医学院耳鼻咽喉科学教授、匹兹堡大学癌症研究所(UPCI)头颈部项目主管Jennif

Blood:阻断一对“好基友”癌基因 有效治疗小鼠白血病

调节细胞分裂的蛋白控制着肿瘤细胞的生长。一项临床试验研究了两个蛋白(CDK4和CDK6)的抑制剂,针对多种类型癌症,如乳腺癌,肺癌和白血病的治疗功效。 在西班牙国家癌症研究中心(CNIO)科学家的带动下,Marcos Malumbres等研究人员在小鼠中证实,同时抑制这两个蛋白CDK4和CDK6比单独抑制某个蛋白更有效。这项研究已经发表在医学杂志Blood上。 Malumbres解释:

Lancet Oncol述评:MYCN在视网膜母细胞瘤发病中起到重要作用

原癌基因的发现改变了我们对肿瘤发生机制的认识。之后,对视网膜母细胞瘤基因(RB1)的确定则预示着另一个观念——恶性疾病的发生具有一定遗传基础,即在生殖细胞和体细胞中肿瘤抑制基因的突变会导致肿瘤的形成。事实上,对肿瘤发生的潜伏期进行分析提示,即使在“责任基因”被发现之前,我们也认识到在罹患遗传性疾病的个体中,如果所残余正常的单个等位基因发生突变则会导致视网膜母细胞瘤的发生,或者在两个等位基因同时发生

Mol Cell:机体细胞癌变前会暂停细胞周期

当细胞察觉有个癌基因在蠢蠢欲动时,它会怎么做呢?科学家们发现,细胞能够发出内部信号停止细胞周期,从而进入保护性不生长状态(至少在一定时间内)。 二十世纪八十年代,科学家们就知道人类基因RAS发生突变能够将细胞送上癌变之路。现在,冷泉港实验室(CSHL)的研究者们解析了,细胞应答RAS基因激活进入静止状态(衰老)的机制。这项研究于八月二十八日发表在Molecular Cell杂志

Mol Cell Biol:鉴别淋巴瘤突变的好坏

  熟悉X战警的人都知道,突变既可以是非常好也可以是非常糟糕,或者介于两者之间。相同的现象确实也发生在肿瘤细胞,肿瘤细胞可能存在的数以百计基因突变使它与人体其它细胞区别开来;科学的挑战是找出哪些突变是有害的以及哪些是无害的。现在,约翰霍普金斯医学院的研究者已经找到了一个将它们区别开来的新方法:他们制备一个与淋巴瘤相关的随机突变基因,检测该突变基因产生的蛋白是如何工作的,并且为肿瘤发生的潜在因子制作

Hum Mol Genet:科学家证实烟草可增加患癌基因活性

香烟留给你的绝对不止衣服和指甲上的呛人气味。一项新的研究找到了有力证据,表明烟草的使用能够在化学上改变和影响那些已知可以增加罹患癌症风险的基因的活性。这项研究或许能够为研究人员提供新的工具,用以评估吸烟人群的癌症风险。 脱氧核糖核酸(DNA)并不是命中注定的。能够影响基因功能的化合物可以与我们的遗传物质结合,从而开启或关闭某些基因。这些所谓的后天修饰能够影响各种各样的特征,例如肥胖和性取向。